Go Pro
OTCMKTS:MCUJF

Medicure Q4 2024 Earnings Report

Medicure logo
$1.91 0.00 (-0.03%)
As of 10:43 AM Eastern

Medicure EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$4.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Earnings Headlines

CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Winnipeg, Manitoba-based specialty pharmaceutical company focused on developing, commercializing and distributing therapies for cardiovascular and related medical conditions. The company serves healthcare markets primarily in North America through its operating subsidiaries and commercial partners.

Medicure’s product portfolio includes AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the treatment of certain patients with acute coronary syndrome and during percutaneous coronary intervention. The company also markets ZYPITAMAG (pitavastatin), an oral statin used to help manage elevated cholesterol levels.

Medicure has historically concentrated on specialty cardiovascular products and has sought to expand its presence through product development, licensing and commercialization activities. The company is led by Dr. Albert D. Friesen, who serves as president and chief executive officer.

View Medicure Profile